Decoy Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Decoy Therapeutics Inc. (NASDAQ: DCOY), formerly known as Salarius Pharmaceuticals, Inc., is a preclinical-stage biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™). This novel category of antivirals is engineered to target shared viral mechanisms conserved across entire virus families, moving beyond the traditional "one-virus, one-drug" model. The company leverages its proprietary IMP3ACT™ (Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology) platform, which integrates machine learning and artificial intelligence tools with high-speed synthesis techniques to rapidly design, optimize, and manufacture peptide conjugate drug candidates. Decoy's initial pipeline is focused on respiratory viruses (including pan-coronavirus threats, influenza, and RSV) and gastrointestinal (GI) cancers.
Research as of 24 Jul 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Strategic relationship with Quantori and Google Cloud established in March 2026 to scale computational peptide design capacity.
Expected impact: Expected to increase computational peptide design capacity by 25x to 100x, significantly accelerating candidate discovery and optimization cycles.
Advancing a multi-virus respiratory program designed to target influenza, coronavirus, and paramyxovirus (RSV and others) families with a single D-MAV.
Expected impact: Aims to address up to 55-70% of viruses causing annual respiratory infections, creating a highly scalable single-shot therapeutic opportunity.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Strategic merger to combine Salarius' resources and public listing with Decoy's proprietary IMP3ACT platform, creating a unified company focused on next-generation peptide-conjugate therapeutics for infectious diseases and oncology.
Financial impact: Resulted in a combined pro forma cash position of approximately $14 million immediately following the merger and closing of the concurrent public offering.
Strategic Partnerships
High. Dramatically increases computational peptide design capacity to accelerate the discovery of Designable Multi-Antivirals (D-MAVs).
Terms: Supported in part by the Google AI startup program.
High. Provides non-dilutive funding and acceleration support through the QuickFire Challenge award to advance antiviral technologies.
Terms: QuickFire Challenge award funding and non-dilutive capital support.